secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cibus, Inc. (CBUS)
CIK:        0001705843
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001628280-23-028651
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cibus Q2 2023 net loss $20.5M; reports business progress with trait transfers and Bayer collaboration
--------------------------------------------------------------------------------

- Net loss of $20.5M ($3.05 per share) vs $2.5M loss in prior-year quarter; cash $50.9M expected into Q1 2024.
- Closed merger of Cibus Global and Calyxt on May 31, 2023; first trait transfers to Nuseed (canola pod shatter) and Nutrien (rice HT1/HT3) completed.
- Opened 32,000 sq ft Oberlin facility in San Diego for semi-automated high-throughput gene editing trait production.
- Entered collaboration with Bayer Ag to evaluate Cibus' Trait Machine platform for precision gene editing.
- EU regulation proposal would treat Cibus' gene-edited traits as 'conventional-like', opening EU market if adopted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1705843/000162828023028651/0001628280-23-028651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1705843/000162828023028651/cbus-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-028651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer